Retrospective characterization of nodal marginal zone lymphoma Journal Article
| Authors: | Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; Horwitz, S. M.; Imber, B. S.; Intlekofer, A. M.; Johnson, W. T.; Khan, N.; Kumar, A.; Lahoud, O. B.; Lue, J. K.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Owens, C. N.; Lia Palomba, M.; Schöder, H.; Vardhana, S. A.; Yahalom, J.; Zelenetz, A. D.; Salles, G.; Straus, D. J. |
| Article Title: | Retrospective characterization of nodal marginal zone lymphoma |
| Abstract: | Nodal marginal zone lymphoma (NMZL) is a rare non-Hodgkin B-cell lymphoma that has historically been difficult to define, though is now formally recognized by the World Health Organization Classification. To better characterize the clinical outcomes of patients with NMZL, we reviewed a sequential cohort of 187 patients with NMZL to describe baseline characteristics, survival outcomes, and time-To-event data. Initial management strategies were classified into five categories: observation, radiation, anti-CD20 monoclonal antibody therapy, chemoimmunotherapy, or other. Baseline Follicular Lymphoma International Prognostic Index scores were calculated to evaluate prognosis. A total of 187 patients were analyzed. The five-year overall survival was 91% (95% confidence interval [CI], 87-95), with a median follow-up time of 71 months (range, 8-253) among survivors. A total of 139 patients received active treatment at any point, with a median follow-up time of 56 months (range, 13-253) among survivors who were never treated. The probability of remaining untreated at five years was 25% (95% CI, 19-33). For those initially observed, the median time to active treatment was 72 months (95% CI, 49-not reached). For those who received at least one active treatment, the cumulative incidence of receiving a second active treatment at 60 months was 37%. Transformation to large B-cell lymphoma was rare, with a cumulative incidence of 15% at 10 years. In summary, our series is a large cohort of uniformly diagnosed NMZL with detailed analyses of survival and time to event analyses. We showed that NMZL commonly presents as an indolent lymphoma for which initial observation is often a reasonable strategy. © 2023 by The American Society of Hematology. |
| Journal Title: | Blood Advances |
| Volume: | 7 |
| Issue: | 17 |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-09-12 |
| Start Page: | 4838 |
| End Page: | 4847 |
| Language: | English |
| DOI: | 10.1182/bloodadvances.2022009587 |
| PUBMED: | 37307213 |
| PROVIDER: | scopus |
| PMCID: | PMC10469082 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: Robert Stuver -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work